INO, US45773H4092

Inovio Pharmaceuticals stock: HC Wainwright cuts 2026 EPS view

Published on 11/17/2026 at 22:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
HC Wainwright lowered its 2026 EPS forecast for Inovio Pharmaceuticals stock to a loss of 0.98 US dollars. The analyst kept a Buy rating and a 5.00 US dollar target.

Analyst forecast and launch outlook

  • HC Wainwright kept a Buy rating and a 5.00 US dollar price target for Inovio Pharmaceuticals.
  • The company is preparing the commercial rollout of VOCERYQ after accelerated FDA approval.
  • HC Wainwright expects a return to positive quarterly EPS in 2027.
INO, US45773H4092, Illustration mit AI erstellt.

HC Wainwright lowered its fiscal 2026 earnings forecast for Inovio Pharmaceuticals in a research report issued on Thursday, November 12, according to MarketBeat. Analyst R. Selvaraju now expects a fiscal 2026 loss of 0.98 US dollars per share, compared with a previous forecast for a loss of 0.73 US dollars per share.

Rating stays positive

HC Wainwright maintained its Buy rating and a 5.00 US dollar price objective. The analyst also forecasts a loss of 0.15 US dollars per share for the fourth quarter of 2026, followed by positive quarterly EPS in the third quarter of 2027.

MarketBeat reported that Inovio posted a third-quarter loss of 0.50 US dollars per share, missing the 0.21 US dollar consensus loss. Revenue was 0.30 million US dollars, below the 2.27 million US dollar estimate.

Commercial launch remains central

Inovio is moving toward the commercial rollout of VOCERYQ, its treatment for adults with recurrent respiratory papillomatosis. The product received accelerated FDA approval, and the company expects ordering and shipping to begin about 60 days after approval, with a full commercial launch targeted for the first quarter of 2027.

Inovio Pharmaceuticals stock traded at 1.48 euros on Lang & Schwarz at 22:54 CET on Tuesday, November 17, 2026.

Inovio Pharmaceuticals

  • Company: Inovio Pharmaceuticals, Inc.
  • ISIN: US45773H4092
  • Ticker: INO
  • Home exchange: Nasdaq
  • Lang & Schwarz quote: 1.48 euros at 22:54 CET on November 17, 2026

The S&P 500 is the relevant US market backdrop for the Nasdaq-listed company: Current S&P 500 market coverage.

More news and analyses on Inovio Pharmaceuticals stock

Disclaimer...
en | US45773H4092 | INO | boerse | 70528825 | bgmi